Dr. Joseph Van Galen is dedicated to advancing patient care through the use of innovative therapies, including stem cell transplantation and cellular immunotherapies such as CAR T and tumor-infiltrating lymphocytes (TIL). While these therapies were initially developed to treat cancer, they are increasingly being explored for application in non-malignant diseases.
As an active clinical and translational researcher, Dr. Van Galen brings extensive experience in both interventional and observational studies. His academic interests focus on the biology and management of myeloid diseases, as well as the investigation of on- and off-target effects of biological and cellular immunotherapies.
Through close collaboration with clinical and laboratory teams, Dr. Van Galen aims to improve the therapeutic index of existing treatments and extend the benefits of immuno-oncology to patient populations that have not yet been reached by these advances.